SG11202003441VA - PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF - Google Patents
PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOFInfo
- Publication number
- SG11202003441VA SG11202003441VA SG11202003441VA SG11202003441VA SG11202003441VA SG 11202003441V A SG11202003441V A SG 11202003441VA SG 11202003441V A SG11202003441V A SG 11202003441VA SG 11202003441V A SG11202003441V A SG 11202003441VA SG 11202003441V A SG11202003441V A SG 11202003441VA
- Authority
- SG
- Singapore
- Prior art keywords
- τβκ
- pyrimidine
- inhibitor compounds
- ικκε
- ικκε inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polymerisation Methods In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573255P | 2017-10-17 | 2017-10-17 | |
| PCT/US2018/056192 WO2019079375A1 (en) | 2017-10-17 | 2018-10-17 | IN / ΙΚΚΕ PYRIMIDINE INHIBITOR COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003441VA true SG11202003441VA (en) | 2020-05-28 |
Family
ID=64110186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003441VA SG11202003441VA (en) | 2017-10-17 | 2018-10-17 | PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11440899B2 (zh) |
| EP (1) | EP3697773A1 (zh) |
| JP (1) | JP7284161B2 (zh) |
| KR (1) | KR20200071756A (zh) |
| CN (1) | CN111247134A (zh) |
| AU (1) | AU2018352701A1 (zh) |
| BR (1) | BR112020007549A2 (zh) |
| CA (1) | CA3078583A1 (zh) |
| IL (1) | IL273892A (zh) |
| MX (1) | MX2020003487A (zh) |
| RU (1) | RU2020115295A (zh) |
| SG (1) | SG11202003441VA (zh) |
| TW (1) | TWI802605B (zh) |
| WO (1) | WO2019079375A1 (zh) |
| ZA (1) | ZA202002825B (zh) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050203092A1 (en) * | 2000-08-08 | 2005-09-15 | Benjamin Elfrida R. | 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| NZ524100A (en) * | 2000-08-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| US8084457B2 (en) * | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| WO2006125616A2 (en) * | 2005-05-25 | 2006-11-30 | Ingenium Pharmaceuticals Ag | Pyrimidine-based cdk inhibitors for treating pain |
| FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| US8530480B2 (en) * | 2007-09-04 | 2013-09-10 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| CA2777762A1 (en) * | 2009-10-12 | 2011-04-21 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon |
| GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| AU2012242777A1 (en) * | 2011-04-12 | 2013-10-31 | Alzheimer's Institute Of America, Inc. | Compositions and therapeutic uses of IKK-related kinase epsilon and TANKbinding kinase 1 inhibitors |
| DE102011112978A1 (de) * | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
| PT2812337T (pt) | 2012-02-09 | 2016-12-14 | Merck Patent Gmbh | Derivados de furo[3,2-b]piridina como inibidores de tbk1 e ikk |
| WO2013175415A1 (en) * | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
| TW201418243A (zh) * | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物 |
| GB201303109D0 (en) * | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
| ES2727376T3 (es) * | 2014-09-26 | 2019-10-15 | Gilead Sciences Inc | Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK |
| WO2017003995A1 (en) * | 2015-06-29 | 2017-01-05 | Merck Patent Gmbh | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| CN111247135A (zh) * | 2017-10-17 | 2020-06-05 | 默克专利股份公司 | 嘧啶ΤΒΚ/ΙΚΚε抑制剂化合物及其用途 |
-
2018
- 2018-10-17 CN CN201880067976.7A patent/CN111247134A/zh active Pending
- 2018-10-17 US US16/756,954 patent/US11440899B2/en active Active
- 2018-10-17 CA CA3078583A patent/CA3078583A1/en active Pending
- 2018-10-17 AU AU2018352701A patent/AU2018352701A1/en not_active Abandoned
- 2018-10-17 EP EP18797387.0A patent/EP3697773A1/en active Pending
- 2018-10-17 BR BR112020007549-3A patent/BR112020007549A2/pt unknown
- 2018-10-17 SG SG11202003441VA patent/SG11202003441VA/en unknown
- 2018-10-17 MX MX2020003487A patent/MX2020003487A/es unknown
- 2018-10-17 WO PCT/US2018/056192 patent/WO2019079375A1/en unknown
- 2018-10-17 TW TW107136568A patent/TWI802605B/zh active
- 2018-10-17 JP JP2020521570A patent/JP7284161B2/ja active Active
- 2018-10-17 RU RU2020115295A patent/RU2020115295A/ru unknown
- 2018-10-17 KR KR1020207013748A patent/KR20200071756A/ko not_active Application Discontinuation
-
2020
- 2020-04-07 IL IL273892A patent/IL273892A/en unknown
- 2020-05-15 ZA ZA2020/02825A patent/ZA202002825B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020115295A3 (zh) | 2021-11-18 |
| TWI802605B (zh) | 2023-05-21 |
| US11440899B2 (en) | 2022-09-13 |
| JP7284161B2 (ja) | 2023-05-30 |
| ZA202002825B (en) | 2023-05-31 |
| CN111247134A (zh) | 2020-06-05 |
| CA3078583A1 (en) | 2019-04-25 |
| WO2019079375A1 (en) | 2019-04-25 |
| IL273892A (en) | 2020-05-31 |
| MX2020003487A (es) | 2020-07-22 |
| US20210214339A1 (en) | 2021-07-15 |
| KR20200071756A (ko) | 2020-06-19 |
| TW201922729A (zh) | 2019-06-16 |
| RU2020115295A (ru) | 2021-11-18 |
| JP2020537661A (ja) | 2020-12-24 |
| EP3697773A1 (en) | 2020-08-26 |
| BR112020007549A2 (pt) | 2020-09-24 |
| AU2018352701A1 (en) | 2020-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| HK1251547A1 (zh) | 嘧啶或吡啶並吡啶酮類化合物及其應用 | |
| GB201708652D0 (en) | Novel compounds and uses | |
| IL269711A (en) | ASK1 inhibitory compounds and their uses | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| GB201714745D0 (en) | New compounds and uses | |
| IL254974B (en) | Crystalline compound of fgfr4 inhibitor and uses thereof | |
| GB201714740D0 (en) | New compounds and uses | |
| IL262400A (en) | Erbb inhibitors and uses thereof | |
| GB201714734D0 (en) | New compounds and uses | |
| IL292488B1 (en) | Pyridineamine-pyridone and pyrimidineamine-pyridone compounds | |
| SG11202004361SA (en) | Quinazolinone compound and application thereof | |
| SG11202003407VA (en) | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| GB201714736D0 (en) | New compounds and uses | |
| IL292482B2 (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| GB201712110D0 (en) | New compounds and uses | |
| GB201700404D0 (en) | Compounds and composistions | |
| ZA202002825B (en) | Pyrimidine τβκ/ικκε inhibitor compounds and uses thereof | |
| GB201720092D0 (en) | New Compounds and uses | |
| GB201719327D0 (en) | New compounds and uses | |
| GB201719233D0 (en) | New compounds and uses | |
| GB201714743D0 (en) | New compounds and uses | |
| GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors |